Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2016 1
2017 2
2018 1
2020 2
2021 1
2022 1
2023 4
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

10 results

Results by year

Filters applied: . Clear all
Page 1
Total neoadjuvant therapy with or without aflibercept in rectal cancer: 3-year results of GEMCAD-1402.
Pesántez D, Ten Hoorn S, Machado I, García-Albéniz X, Rodríguez-Salas N, Heredia-Soto V, Viñal D, Pericay C, García-Carbonero R, Losa F, Alonso V, Vera R, Feliu Batlle J, Gallego J, Salud A, Nogué M, Layos L, Montagut C, Capdevila J, Vermeulen L, Maurel J, Fernandez-Martos C. Pesántez D, et al. J Natl Cancer Inst. 2023 Dec 6;115(12):1497-1505. doi: 10.1093/jnci/djad120. J Natl Cancer Inst. 2023. PMID: 37405857 Clinical Trial.
Determinants of activity and efficacy of anti-PD1/PD-L1 therapy in patients with advanced solid tumors recruited in a clinical trials unit: a longitudinal prospective biomarker-based study.
García-Corbacho J, Indacochea A, González Navarro AE, Victoria I, Moreno D, Pesántez D, Angelats L, Modrego-Sanchez A, Sanfeliu E, Castillo O, Blasco P, Mezquita L, Viñolas N, Nogué M, Galván P, Adamo B, Basté N, Sauri T, Juan M, Prat A, Schettini F. García-Corbacho J, et al. Among authors: pesantez d. Cancer Immunol Immunother. 2023 Jun;72(6):1709-1723. doi: 10.1007/s00262-022-03360-9. Epub 2023 Jan 10. Cancer Immunol Immunother. 2023. PMID: 36625938 Free PMC article.
Mutational Status of SMAD4 and FBXW7 Affects Clinical Outcome in TP53-Mutated Metastatic Colorectal Cancer.
Lahoz S, Rodríguez A, Fernández L, Gorría T, Moreno R, Esposito F, Oliveres H, Albiol S, Saurí T, Pesantez D, Riu G, Cuatrecasas M, Jares P, Pedrosa L, Pineda E, Postigo A, Castells A, Prat A, Maurel J, Camps J. Lahoz S, et al. Among authors: pesantez d. Cancers (Basel). 2022 Nov 30;14(23):5921. doi: 10.3390/cancers14235921. Cancers (Basel). 2022. PMID: 36497403 Free PMC article.
Bisalbuminemia in a patient with metastatic lung cancer.
Pesántez D, Zamora C, Crespo J. Pesántez D, et al. Med Clin (Barc). 2017 Feb 9;148(3):145-146. doi: 10.1016/j.medcli.2016.11.003. Epub 2016 Dec 16. Med Clin (Barc). 2017. PMID: 27989464 English, Spanish. No abstract available.
Unexpected Durable Complete Response With Anti-PD-L1 Blockade in Metastatic Undifferentiated Pleomorphic Sarcoma: A Case Report With Host and Tumor Biomarker Analysis.
Pesántez D, Indacochea A, Angelats L, Sirico M, Victoria I, Sanfeliu E, Teixido C, González-Navarro AE, Galván P, Brasó-Maristany F, Jares P, Juan M, Prat A, Schettini F, García-Corbacho J. Pesántez D, et al. JCO Precis Oncol. 2023 Sep;7:e2300051. doi: 10.1200/PO.23.00051. JCO Precis Oncol. 2023. PMID: 37856765 No abstract available.
ERBB2 mRNA Expression and Response to Ado-Trastuzumab Emtansine (T-DM1) in HER2-Positive Breast Cancer.
Griguolo G, Brasó-Maristany F, González-Farré B, Pascual T, Chic N, Saurí T, Kates R, Gluz O, Martínez D, Paré L, Tsvetkova V, Pesantez D, Vidal M, Adamo B, Muñoz M, Galván P, Barberá L, Cuatrecasas M, Christgen M, Kreipe H, Monge-Escartín I, Villagrasa P, Soy D, Giarratano T, Dieci MV, Conte P, Harbeck N, Guarneri V, Prat A. Griguolo G, et al. Among authors: pesantez d. Cancers (Basel). 2020 Jul 14;12(7):1902. doi: 10.3390/cancers12071902. Cancers (Basel). 2020. PMID: 32674482 Free PMC article.
Correction to: Determinants of activity and efficacy of anti-PD1/PD-L1 therapy in patients with advanced solid tumors recruited in a clinical trials unit: a longitudinal prospective biomarker-based study.
García-Corbacho J, Indacochea A, González Navarro AE, Victoria I, Moreno D, Pesántez D, Angelats L, Modrego-Sanchez A, Sanfeliu E, Castillo O, Blasco P, Mezquita L, Viñolas N, Nogué M, Galván P, Adamo B, Basté N, Sauri T, Juan M, Prat A, Schettini F. García-Corbacho J, et al. Among authors: pesantez d. Cancer Immunol Immunother. 2023 Jun;72(6):1725-1726. doi: 10.1007/s00262-023-03396-5. Cancer Immunol Immunother. 2023. PMID: 36809405 Free PMC article. No abstract available.